Pertuzumab and Biosimilars
About Pertuzumab [HER2+ antibody]
Pertuzumab It is the first-in-class of a kind of medication called a “epidermal growth factor receptor (HER) dimerization inhibitor” — it inhibits the dimerization of HER2 with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation.
Pertuzumab used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.
Commercial Products
| Attributes | RD code | Brand Name | Approved | Owner | Area | WebSite |
|---|---|---|---|---|---|---|
| Originator | J9306 | Perjeta® | 2012 | Genentech By Roche | USA | roche.com |
| Biosimilar | TNB-383B | CNN：帕乐坦® | 2024 | CHIATHAI TIANQIONG(CNN：正大天晴药业) | China | cttq.com |
| Biosimilar | QL1209 | CNN：安赛珠® | 2024 | QiLu Pharma(CNN：齐鲁制药) | China | qilu-pharma.com |
Business Cooperation
- You wish to purchase this product (Pertuzumab).
- Do you want to obtain the distribution rights for this product (Pertuzumab)?
Related Products
-
About Adalimumab [TNF inhibitor] Adalimumab is an anti-TNF drug used for various types of arthritis. Adalimumab is used to treat various autoimmune […]
-
About Trastuzumab [HER2+ antibody] Trastuzumab blocks the activity of HER2 and triggers a type of immune reaction that kills cells that […]
-
About Rituximab [anti-CD20 antibody] Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the […]
